# Contents

<table>
<thead>
<tr>
<th>Author biographies</th>
<th>vii</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbreviations</td>
<td>ix</td>
</tr>
<tr>
<td>Dedication</td>
<td>xiii</td>
</tr>
</tbody>
</table>

## 1 Introduction

- Historical perspective  
- Epidemiology  
- Etiology  
- Clinical manifestations  
- Pathophysiology  
- References  

## 2 Diagnosis

- Diagnostic laboratory tests  
- Differential diagnosis  
- Clinical risk scores  
- References  

## 3 Monitoring response to treatment

- Hematological response  
- Cytogenetic response  
- Molecular monitoring methods  
- Rising $BCR-ABL$ levels  
- Pharmacokinetics  
- Monitoring protocol in different clinical settings  
- References  

## 4 Management of patients with chronic myeloid leukemia

- Current approach to treatment  
- Which tyrosine kinase inhibitor to use?  
- Determining the treatment goals  
- Achieving treatment goals
Identifying high-risk patients based on early molecular response 46
Risk-adapted therapy 47
Other promising frontline approaches 48
References 49

5 Challenges of treatment: tyrosine kinase inhibitor-resistant chronic myeloid leukemia 53
Mechanisms of resistance 53
Therapeutic options for patients who fail frontline therapy 59
Other tyrosine kinase inhibitors after failure of frontline therapy 60
Allogeneic stem cell transplantation 61
References 62
Handbook of Chronic Myeloid Leukemia
Hughes, T.P.; Ross, D.M.; Melo, J.V.
2014, XIII, 65 p. 14 illus., 12 illus. in color., Softcover
ISBN: 978-3-319-08349-0